Yang Xiaolin, Sun Hongzhi, Song Ying, Yang Li, Liu Haibo
Department of Geriatrics, the First Hospital of Jilin University, Changchun, China.
Department of Emergency and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, China.
PeerJ. 2020 Jul 16;8:e9535. doi: 10.7717/peerj.9535. eCollection 2020.
Spindle pole body component 25 (SPC25) plays a vital role in many cellular processes, such as tumorigenesis. However, the clinical significance of SPC25 in hepatocellular carcinoma (HCC) has not been investigated. This study aimed to explore the expression patterns of SPC25 in HCC and non-neoplastic tissues and to investigate the diagnostic and prognostic values of SPC25.
The expression of SPC25 was examined in 374 HCC issues and 50 non-neoplastic tissues from The Cancer Genome Atlas (TCGA) cohort. The diagnostic and prognostic values of SPC25 were analyzed via receiver operating characteristic (ROC) curve and survival analyses, respectively. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors and to establish a nomogram. The diagnostic and prognostic values were further validated in an external cohort from the International Cancer Genome Consortium (ICGC) database.
The expression of SPC25 in HCC tissues was significantly higher than that in normal tissues in both cohorts (all < 0.001). The ROC curve analysis indicated that SPC25 expression has high diagnostic value in HCC with area under the curve (AUC) value of 0.969 (95% confidence interval [CI] [0.948-0.984]) and 0.945 (95% CI [0.920-0.965]) for TCGA and ICGC cohorts, respectively. Patients with HCC exhibiting high SPC25 expression were associated with worse prognosis than those exhibiting low SPC25 expression in both cohorts (all < 0.001). SPC25 was independently associated with overall survival in both cohorts (all < 0.001). The concordance indices of the nomogram for predicting overall survival in TCGA and ICGC cohorts were 0.647 and 0.805, respectively, which were higher than those of the American Joint Committee on Cancer (AJCC) staging system.
SPC25 was upregulated in HCC and independently predicted poor overall survival of patients with HCC. Therefore, SPC25 is an effective diagnostic and prognostic biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system to predict prognosis of HCC.
纺锤极体成分25（SPC25）在许多细胞过程中发挥着至关重要的作用，如肿瘤发生。然而，SPC25在肝细胞癌（HCC）中的临床意义尚未得到研究。本研究旨在探讨SPC25在HCC组织和非肿瘤组织中的表达模式，并研究SPC25的诊断和预后价值。
检测了癌症基因组图谱（TCGA）队列中374例HCC组织和50例非肿瘤组织中SPC25的表达。分别通过受试者工作特征（ROC）曲线和生存分析来分析SPC25的诊断和预后价值。采用单因素和多因素Cox回归分析来确定预后因素并建立列线图。在国际癌症基因组联盟（ICGC）数据库的一个外部队列中进一步验证了诊断和预后价值。
在两个队列中，HCC组织中SPC25的表达均显著高于正常组织（均P<0.001）。ROC曲线分析表明，SPC25表达在HCC中具有较高的诊断价值，TCGA队列和ICGC队列的曲线下面积（AUC）值分别为0.969（95%置信区间[CI][0.948 - 0.984]）和0.945（95%CI[0.920 - 0.965]）。在两个队列中，SPC25高表达的HCC患者的预后均比SPC25低表达的患者差（均P<0.001）。在两个队列中，SPC25均与总生存期独立相关（均P<0.001）。TCGA队列和ICGC队列中预测总生存期的列线图的一致性指数分别为0.647和0.805，均高于美国癌症联合委员会（AJCC）分期系统。
SPC25在HCC中上调，并独立预测HCC患者的不良总生存期。因此，SPC25是HCC有效的诊断和预后生物标志物。基于SPC25的列线图在预测HCC预后方面比AJCC分期系统更准确、更有用。
